FY2028 Earnings Estimate for XFOR Issued By HC Wainwright

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Equities research analysts at HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for shares of X4 Pharmaceuticals in a research note issued to investors on Friday, February 7th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.02 per share for the year, down from their prior estimate of $0.04. HC Wainwright has a “Buy” rating and a $1.50 price objective on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ FY2029 earnings at $0.16 EPS.

Separately, Stifel Nicolaus lowered their price target on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, November 14th.

X4 Pharmaceuticals Stock Down 3.8 %

XFOR stock opened at $0.51 on Monday. The firm has a market capitalization of $86.88 million, a PE ratio of -5.66 and a beta of 0.12. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $1.60. The stock’s 50 day moving average is $0.59 and its 200-day moving average is $0.60.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several large investors have recently modified their holdings of the stock. GSA Capital Partners LLP purchased a new position in X4 Pharmaceuticals in the third quarter valued at approximately $340,000. AQR Capital Management LLC lifted its position in shares of X4 Pharmaceuticals by 1,080.3% during the 2nd quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after buying an additional 388,115 shares during the last quarter. State Street Corp grew its stake in shares of X4 Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after acquiring an additional 189,105 shares during the period. Barclays PLC increased its holdings in X4 Pharmaceuticals by 196.0% in the 3rd quarter. Barclays PLC now owns 277,682 shares of the company’s stock worth $185,000 after acquiring an additional 183,861 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in X4 Pharmaceuticals by 233.0% in the 4th quarter. SG Americas Securities LLC now owns 183,152 shares of the company’s stock valued at $134,000 after acquiring an additional 128,148 shares during the period. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Insider Buying and Selling at X4 Pharmaceuticals

In related news, CFO Adam S. Mostafa sold 74,773 shares of the firm’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Paula Ragan sold 76,473 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the completion of the transaction, the chief executive officer now owns 1,087,386 shares in the company, valued at approximately $489,323.70. The trade was a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 202,663 shares of company stock worth $91,198. Insiders own 1.62% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.